• NuCana expects its cash position to fund operations into 2029; cash and cash equivalents totaled approximately $25.9 million at June 30, 2026.
• NUC-7738's Phase 2 melanoma expansion with pembrolizumab remains ongoing, with recruitment completion and expansion data expected in 2026.
• Plans include obtaining FDA feedback on a registration strategy and a first-line Phase 1b melanoma study combining NUC-7738 with Opdualag.
• The randomized NUC-3373 colorectal cancer trial stopped early in 2024 because an interim analysis indicated superior progression-free survival was unlikely.
• Future NUC-3373 development may target combinations aligned with its mechanism, including immunomodulatory treatments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.